RecruitingNot ApplicableNCT06168032

COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research

Efficacy of COVID-19 Booster-Dose Vaccine for Re-infection Precaution and Dynamics of Specific Serum Antibodies in the Management of Lung Cancer Patients With Systemic Anti-cancer Treatment

Sponsor

Peking Union Medical College Hospital

Enrollment

1,224 participants

Start Date

Dec 8, 2023

Study Type

INTERVENTIONAL

Conditions

Lung Cancer Chemotherapy Immune Checkpoint Inhibitor COVID-19 Recurrent Vaccination Antibody

Summary

A prospective, open-label and parallel non-randomized control trial and biomarker research study is intended to compare incidence of repeated COVID-19 infection, severe pneumonitis and mortality between lung cancer patients undergoing systemic antitumor therapies who get vaccinated with 1 booster dose(majorly against XBB) and those who refuse. Meanwhile, a biomarker research is designed to monitor serum level dynamics of specific antibodies against COVID-19,analyze its correlation with incidence of breakthrough infection and further explore optimal periods for vaccination.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is looking at how well COVID-19 vaccines protect lung cancer patients from getting COVID-19 again. It is also studying how the immune system responds to both cancer treatment and vaccination at the same time. **You may be eligible if...** - You are 18 years or older - You have been diagnosed with lung cancer confirmed by biopsy or lab testing - You are currently receiving cancer treatment (chemotherapy, immunotherapy, targeted therapy, or a combination) - You have a history of COVID-19 infection - Your general health is good enough for cancer treatment (performance score 0-2) **You may NOT be eligible if...** - Your life expectancy is less than 3 months - It has been less than 3 months since your last COVID-19 infection - You cannot come back to the hospital for follow-up appointments - You are allergic to COVID-19 vaccines - You have had severe (grade 3 or higher) side effects from cancer treatment or immunization Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

BIOLOGICALAny Chinese government-recommended COVID-19 booster vaccine

Any Chinese government-recommended COVID-19 booster vaccine(such as Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine(Sf9 Cell) and so on) will be once administered in the sixth month after COVID19 infection.